“Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI)”. 2023. SKIN The Journal of Cutaneous Medicine 7 (2): s120. https://doi.org/10.25251/skin.7.supp.120.